SCHEMBL15094666

SCHEMBL15094666

COC(=O)c1cccc(C(=O)Nc2cccc(-c3nnn[nH]3)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ TP53 P04637 1/20 0.53
▸ MEN1 O00255 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GPR17 Q13304 1/20 0.50
▸ PLAU P00749 4/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ ROCK2 O75116 2/20 0.47
▸ ABL1 P00519 1/20 0.46
▸ RIN1 Q13671 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ PLAT P00750 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15094744 0.90 KMT2A (0.49) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL31680549 0.88 MMP2 (0.54) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1505455 0.87 GABRG2 (0.50) RAB9ATP53PLAUNPC1MAPT
SCHEMBL21067860 0.85 KMT2A (0.58) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL21812212 0.83 MAOA (0.54) RAB9ASMN1; SMN2MEN1KMT2ANPC1
SCHEMBL15094758 0.81 RXFP1 (0.48) RXFP1
SCHEMBL9589707 0.81 NPC1 (0.49) RAB9ASMN1; SMN2TP53MEN1KMT2A
SCHEMBL21812214 0.81 ROCK2 (0.47) TP53MEN1KMT2ALMNAMAPT
SCHEMBL1249670 0.81 NPC1 (0.55) RAB9ATP53MEN1KMT2APLAU
SCHEMBL15094761 0.80 BRAF (0.50) RAB9AMEN1KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604493-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2020-03-31 — — US disclosed
US-20170088524-A1 Compositions, Methods of Use, And Methods of Treatment UNIVERSITY OF SOUTH FLORIDA 2017-03-30 — — US disclosed
US-9556131-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2017-01-31 — — US disclosed
US-20140378516-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT UNIVERSITY OF SOUTH FLORIDA 2014-12-25 — — US disclosed
EP-2800568-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT University Of South Florida (US) 2014-11-12 — — EP disclosed
WO-2013103760-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT UNIVERSITY OF SOUTH FLORIDA (US) 2013-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378516-A1 COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT LIPA, LCT, GAA RAB9A 2492/4885SMN1; SMN2 789/4885TP53 2502/4885
US-10604493-B2 Compositions, methods of use, and methods of treatment LIPA, LCT, GAA RAB9A 2492/4885SMN1; SMN2 789/4885TP53 2502/4885
US-20170088524-A1 Compositions, Methods of Use, And Methods of Treatment LIPA, LCT, GAA RAB9A 2492/4885SMN1; SMN2 789/4885TP53 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback